Abstract

Summary

Optogenetic therapies using light-sensitive proteins inserted into retinal neurons offer a genotype-agnostic approach to restoring vision in degenerative eye diseases such as retinitis pigmentosa and glaucoma. While still largely in pre-clinical and early clinical trial phases, these advances have implications for understanding retinal photoreceptor biology and may eventually inform lighting design considerations for visually impaired populations.
Abstract

Key Findings

  • Optogenetic approaches can restore light sensitivity by inserting light-sensitive proteins into downstream retinal neurons that have lost intrinsic photoreceptor function, applicable across all genetic forms of retinal dystrophy.
  • The CRY-CIBN optogenetic system has been applied to animal models of glaucoma, implicating OCRL in the regulation of intraocular pressure in trabecular meshwork.
  • Multiple optogenetic therapeutic options are in pre-clinical and phase I/II clinical trials for major blinding diseases including glaucoma and retinitis pigmentosa.
Categories

Categories

Eye Health & Vision: Reviews optogenetic approaches for restoring vision in degenerative retinal diseases including glaucoma and retinitis pigmentosa.
The Science of Light: Discusses light-sensitive proteins and photoreceptor biology as therapeutic tools, relevant to understanding photoreceptor function and light-cell interactions.
Authors

Author(s)

PP Prosseda, M Tran, T Kowal, B Wang, Y Sun
Publication Date

Publication Year

2022
Citations

Number of Citations

19
View more publications